Phosphodiesterase inhibitors for the treatment of pulmonary hypertension
Open Access
- 5 March 2008
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 32 (1), 198-209
- https://doi.org/10.1183/09031936.00124007
Abstract
The pulmonary vascular bed is both a source of and target for a number of vasoactive factors. Among the most important for pulmonary vascular homeostasis are factors that utilise cyclic guanosine monophosphate (cGMP) as an intracellular second messenger. These include nitric oxide and the natriuretic peptide family (atrial, brain and C-type natriuretic peptides). In the search for therapeutic strategies that engage the cGMP signalling pathway for the treatment of pulmonary arterial hypertension (PAH), inhibition of cGMP metabolism by phosphodiesterase type 5 (PDE5)-targeted compounds has proven most successful to date. One PDE5 inhibitor, sildenafil, has been shown to improve pulmonary haemodynamics and exercise capacity in patients with PAH and is now an approved treatment. Others are under investigation. An interesting, although still tentative, observation is the potential of sildenafil to reduce pulmonary vascular resistance without adversely affecting ventilation–perfusion matching. Another is the expression of phosphodiesterase type 5 in the hypertrophied right ventricle. These data suggest that phosphodiesterase type 5 inhibitors may have effects that distinguish them from other treatments for pulmonary hypertension and merit further study.Keywords
This publication has 79 references indexed in Scilit:
- Role of oral sildenafil in severe pulmonary arterial hypertension: Clinical efficacy and dose response relationshipInternational Journal of Cardiology, 2007
- Natriuretic PeptidesHypertension, 2007
- Natriuretic Peptides and Nitric Oxide Stimulate cGMP Synthesis in Different Cellular CompartmentsThe Journal of general physiology, 2006
- High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitorsBiochemical and Biophysical Research Communications, 2005
- Evaluation of vardenafil and sildenafil on cardiac repolarizationThe American Journal of Cardiology, 2004
- Direct activation of PDE5 by cGMPThe Journal of cell biology, 2003
- TadalafilDrugs, 2003
- Regulation of Human PDE5A2 Intronic Promoter by cAMP and cGMP: Identification of a Critical Sp1-Binding SiteBiochemical and Biophysical Research Communications, 2001
- Identification of Three Alternative First Exons and an Intronic Promoter of Human PDE5A GeneBiochemical and Biophysical Research Communications, 2000
- Characterization of the Isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021Cellular Signalling, 1996